bFGF promotes chondrosarcoma resistance to doxorubicin by upregulating the expression of X-ray repair cross-complementing protein 5 (XRCC5), while bFGF is the ligand of FGFR1 (47). Here, XRCC5 is linked to chondrosarcoma.